Synonyms: 2,6-dichloro-alpha-(4-chlorophenyl)-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3H)-yl)benzeneacetonitrile; Clinacox; NCGC00168785-01; R64,433; R 64433; (p-Chlorophenyl)(2,6-dichloro-4-(4,5-dihydro-3,5-dioxo-as-triazin-2(3H)-yl)phenyl)acetonitrile; DCL; (p-chlorophenyl)[2,6-dichloro-4-(4,5-dihydro-3,5-dioxo-as-triazin-2(3H)-yl)phenyl]acetonitrile; 2,6-Dichloro-alpha-(4-chlorophenyl)-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3H)-yl)benz-eneacetonitrile; Benzeneacetonitrile, 2,6-dichloro-alpha-(4-chlorophenyl)-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3H)-yl)-; R-64433; Diclazurilo; Diclazurilum; 2,6-Dichloro-alpha-(4-chlorophenyl)-4-[4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3H)-yl]benzeneacetonitrile; 2-(4-chlorophenyl)-2-(2,6-dichloro-4-(3,5-dioxo-4,5-dihydro-1,2,4-triazin-2(3H)-yl)phenyl)acetonitrile; SR-05000001484; Nuoqiu; Diclazuril [USAN:USP:INN:BAN]; (4-chlorophenyl)[2,6-dichloro-4-(3,5-dioxo-4,5-dihydro-1,2,4-triazin-2(3H)-yl)phenyl]acetonitrile; diclazuril; 2,6-dichloro-alpha-(4-chlorophenyl)-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3H)-yl)benzeneacetonitrile; AC1L9UTR; Diclazuril (USAN/INN); DSSTox_CID_26787; DSSTox_RID_81905; DSSTox_GSID_46787; SCHEMBL126138; CHEMBL284733; DTXSID4046787; CHEBI:95118; R 64433; ZSZFUDFOPOMEET-UHFFFAOYSA-N; HMS2089N18; HMS3655D11; HMS3715D21; Pharmakon1600-01502348; BCP12257; HY-B0357; Tox21_112645; BBL005225; BDBM50088493; R-64433; GP6995; NSC759642; STL135982; AKOS005746928; CCG-213044; CS-2411; KS-5064; MCULE-4598187571; NSC-759642; SB18820; DICLAZURIL; NCGC00168785-02; AC-12108; AN-34253; BC204051; CC-26555; SC-13717; AB0105674; AB2000434; CAS-101831-37-2; D5457; 101831-37-2; FT-0603078; SW199606-2; D03794; Diclazuril, VETRANAL(TM), analytical standard; AB01562968_01; AB01562968_02; 831D372; A800467; C-21857; P 64433; Clinacox; I01-0373; J-000501; SR-05000001484-1; SR-05000001484-2; Diclazuril, United States Pharmacopeia (USP) Reference Standard; 2-[4-(4-chloro-alpha-cyanobenzyl)-3,5-dichlorophenyl]-1,2,4-triazine-3,5(2H,4H)-dione; Diclazuril for system suitability, European Pharmacopoeia (EP) Reference Standard; 2,6-Dichloro-.alpha.-(4-chlorophenyl)-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3H)-yl)benzeneacetonitrile; 2,6-Dichloro-|A-(4-chlorophenyl)-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3H)-yl)-benzeneacetonitrile; 2,6-Dichloro-|A-(4-chlorophenyl)-4-[4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3H)-yl]benzeneacetonitrile; Vecoxan; 2,6-dichloro-alpha-(4-chlorophenyl)-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3H)-yl)-benzeneacetonitrile; 2,6-dichloro-alpha-(4-chlorophenyl)-4-[4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3h)-yl]benzeneacetonitr; 2-[4-[3,5-bis(oxidanylidene)-1,2,4-triazin-2-yl]-2,6-bis(chloranyl)phenyl]-2-(4-chlorophenyl)ethanenitrile; null; Coxiril; DCZL; Diclazurilum [Latin]; Diclazurilo [Spanish]; UNII-K110K1B1VE; C17H9Cl3N4O2; 2-(4-chlorophenyl)-2-[2,6-dichloro-4-(3,5-dioxo-1,2,4-triazin-2-yl)phenyl]acetonitrile; Diclazuril [USAN:BAN:INN]; Diclazuril [USAN:INN:BAN]; K110K1B1VE; DRG-0079; C17-H9-Cl3-N4-O2; CID456389; DL-164; s2028; CS-O-01281; Diclazuril, 98% - 100MG 100mg;